



ABOUT ARRAY BIOPHARMA



Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a *BRAF*^{V600E} or *BRAF*^{V600K} mutation in the U.S. and with partners in other major worldwide markets. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in *BRAF*-mutant colorectal cancer. Array's pipeline includes several additional programs currently in registration trials being advanced by us or current license-holders.

BY THE NUMBERS



NASDAQ	ARRY
Market Capitalization	>\$5B
Staff	300
Cash (12/31/18)	\$478M
Headquarters	Boulder, CO

www.arraybiopharma.com

Info@arraybiopharma.com

303.381.6600

3200 Walnut Street
Boulder, Colorado 80301

Follow us @arraybiopharma
on Twitter and LinkedIn

Maximizing Success of Encorafenib & Binimetinib is Array's Top Priority

Significant Milestones Achieved...

... Important Value-Drivers



BRAFTOVI + MEKTOVI launched in US

- Positive reception from U.S. melanoma healthcare providers
- BRAFTOVI + MEKTOVI approved in Europe and Japan for advanced *BRAF*-mutant melanoma

- Continued penetration in melanoma
- European commercial expansion



BRAF-MUTANT METASTATIC CRC

- BEACON CRC Safety Lead-in at ASCO GI: **15.3 months mature median OS**
- FDA Breakthrough Therapy Designation
- Planned interim analysis after consultation with FDA and EMA; analysis for U.S. sNDA based primarily on ORR and duration of response

- Enrollment completed
- Plan to seek accelerated approval in the U.S. if supported by positive interim results
- Topline results 1H19
- Trial posted to ClinicalTrials.gov



Encorafenib + Binimetinib + Cetuximab in First-line *BRAF*^{V600E}-mutant mCRC

- Currently enrolling

MSS CRC AND OTHER CANCERS

Binimetinib + I/O Collaborations



Bristol-Myers Squibb



COST SHARING

BEACON CRC co-funding: Pierre Fabre (40%), Ono Pharmaceuticals (milestone payments), Merck KGaA (cetuximab supply)

Strategy

We are a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Our strategy includes:



Inventing best-in-class small molecule drugs for patient populations which have significant unmet medical need

Conducting clinical trials which maximize the overall value of our programs for patients and Array



Building and maintaining an oncology focused sales, marketing and medical organization to commercialize our products in the U.S

Selectively partnering with early-stage research programs outside oncology



Partnerships

ONO ONO PHARMACEUTICAL CO.,LTD.

AstraZeneca

Pierre Fabre

AMGEN

AsahiKASEI